Multi-gene test identifies early breast cancer patients who can be spared chemo

Researchers have shown for the first time that it is possible to use a multi-gene test to identify early breast cancer patients who can be spared chemo and who will still be alive and well five years after diagnosis. Results from the phase III PlanB trial, presented at EBCC10, show that showed that 94 percent of women assessed as at low risk of a recurrence of their disease by the 21-gene Recurrence Score (Oncotype DX) test were disease-free after five years. —> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail